Back to search
FDAFDA · Food and drugs·Recall number Z-0178-2024

Robotics Pack, REF SJVO56B

Published November 1, 2023 · Recall initiated: September 1, 2023

Summary

FDA records medical device Class II recall Z-0178-2024, published November 1, 2023 and initiated September 1, 2023. Recalling firm: American Contract Systems, Inc.; Status: Ongoing; Reported quantity: 112 cases; Lot: UDI/DI 00191072122339, Lot Numbers: 965231. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

During an internal investigation, ACS identified that the components, I.V. Cath (part number 4252535-02) and Adhesive Dermabond (part number DHVM12) were inadvertently subjected to the ACS sterilization process and exposed to EO and higher temperatures than approved by the component manufacturer. As a result, the components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) have higher than specified EO residuals.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
American Contract Systems, Inc.
Distributor
US Nationwide distribution in the states of FL, IA.
Lot
UDI/DI 00191072122339, Lot Numbers: 965231
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Robotics Pack, REF SJVO56B recalled?

Yes. FDA published recall Z-0178-2024 on November 1, 2023. Reported hazard: During an internal investigation, ACS identified that the components, I.V. Cath (part number 4252535-02) and Adhesive Dermabond (part number DHVM12) were inadvertently subjected to the ACS sterilization process and exposed to EO and higher temperatures than approved by the component manufacturer. As a result, the components may (1) have a loss/lack of functionality, (2) loss of drug efficacy, if applicable, and (3) have higher than specified EO residuals.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail